<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04507438</url>
  </required_header>
  <id_info>
    <org_study_id>SH201804</org_study_id>
    <nct_id>NCT04507438</nct_id>
  </id_info>
  <brief_title>The Effect of Donepezil on Glycemic Control in Type II Diabetics</brief_title>
  <official_title>The Effect of Donepezil on Glycemic Control in Type II Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish the effectiveness of the drug Donepezil in treating&#xD;
      Type 2 Diabetes Mellitus compared to a control treatment. Donepezil is not approved by the&#xD;
      FDA to treat Type 2 Diabetes Mellitus and its use in this research is experimental. 50&#xD;
      patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) will be randomized to&#xD;
      either the donepezil treatment group or the control group after screening. (25 patients in&#xD;
      each arm; a total of 50 patients). Both men and women shall be enrolled.Donepezil shall be&#xD;
      orally administered to the study group. Control group will get an orally administered placebo&#xD;
      which is an inert compound, lactose. Wk0 will be the randomization visit. The patients will&#xD;
      take the drug for 8 weeks and the last follow up visit will be the last day of week 8.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blinded, treatment-controlled, parallel design to&#xD;
      investigate the effect of donepezil (administration of 5-10 mg of donepezil daily, orally,&#xD;
      over 8 week period) on clinical outcomes reflecting diabetic control. The research assistant&#xD;
      will not be blinded. The investigator and patient shall be blinded. A computer program will&#xD;
      be used to randomize the patients.&#xD;
&#xD;
      50 patients with Type 2 Diabetes Mellitus (Adult Onset Diabetes Mellitus) will be randomized&#xD;
      to either the donepezil treatment group or the control group after screening. (25 patients in&#xD;
      each arm; a total of 50 patients). Both men and women shall be enrolled.&#xD;
&#xD;
      As many patients as required to meet the enrollment numbers shall be screened. Patients will&#xD;
      be monitored daily for blood pressure, glucose levels and heart rate, during the period of&#xD;
      hospitalization. Adjustments in insulin or oral hypoglycemic, blood pressure and heart rate&#xD;
      control medications will occur during this time. Follow up visits will be made as required&#xD;
      and at the end of week 8.&#xD;
&#xD;
      Donepezil shall be orally administered to the study group. Control group will get an orally&#xD;
      administered placebo which is an inert compound, lactose.&#xD;
&#xD;
      Wk0 will be the randomization visit. The patients will take the drug for 8 weeks and the last&#xD;
      follow up visit will be the last day of week 8.&#xD;
&#xD;
      Any anticholinergic drugs will be eliminated from the patients' medical regimen with the&#xD;
      exception for inhaled anticholinergic. There is no known major contraindication of&#xD;
      acetylcholinesterase inhibitors (like for eg: galantamine, rivastigmine and donepezil)&#xD;
      Patients shall be monitored closely for vagotonic effect. Acetylcholine is known to have a&#xD;
      vagotonic effect lowering heart rate and blood pressure. Therefore, during the course of&#xD;
      administration of the drug close attention to heart rate and blood pressure will be a&#xD;
      significant part off the clinical management of patients. If the patients are on beta&#xD;
      blockers, their beta blocker dose will be closely monitored and adjusted as required.&#xD;
&#xD;
      Proton pump inhibitors will be used to guard against any possible GI bleed. 40 mg of&#xD;
      pantoprazole once daily.&#xD;
&#xD;
      Patient will be observed for seizures. The patients will be examined for pulmonary&#xD;
      exacerbation during treatment in the hospital. If the pulmonary status deteriorates they will&#xD;
      be eliminated from the study. The medication administration will not start sooner than 24 hrs&#xD;
      after surgery. Patients shall be observed for exaggerated response from anesthesia.&#xD;
&#xD;
      Only lipid profile and fasting blood sugar has to be done fasting. As many tests as possible&#xD;
      shall be combined and done at the same time to avoid multiple needle pricks to the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin A1C</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood urea nitrogen</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Change will be assessed by reviewing blood urea nitrogen/creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatinine</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change will be assessed by reviewing blood urea nitrogen/creatinine</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>8 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in albumin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Weight and albumin will be monitored to asses change in nutritional status</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Donepezil treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 5mg or 10 mg of donepezil daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil 5-10 Mg Oral Tablet</intervention_name>
    <description>Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period</description>
    <arm_group_label>Donepezil treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo oral tablet administered daily for an 8 week period</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 50 with Type 2 Diabetes Mellitus, regardless of&#xD;
             co-morbidities including renal and vascular insufficiency, Cardiovascular Autonomic&#xD;
             Neuropathy, Hypertension, Chronic Obstructive Pulmonary Disease or Coronary Disease&#xD;
             will be selected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 50&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Patients who are lactose intolerance&#xD;
&#xD;
          -  Patients with an allergy to Donepezil&#xD;
&#xD;
          -  Prothrombin Time and International Normalized Ratio value greater than 1.25&#xD;
&#xD;
          -  Pre-menopausal women and patients allergic to Donepezil are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephen Wills, MD</last_name>
    <phone>410-822-1000</phone>
    <phone_ext>5226</phone_ext>
    <email>swills@umm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland Shore Regional Health</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Wills, MD</last_name>
      <phone>410-822-1000</phone>
      <phone_ext>5226</phone_ext>
      <email>swills@umm.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Stephen Wills</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

